{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:50:36Z","timestamp":1768258236953,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T00:00:00Z","timestamp":1364342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s11239-013-0911-2","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T11:23:45Z","timestamp":1364297025000},"page":"212-222","source":"Crossref","is-referenced-by-count":26,"title":["Practical issues, limitations, and periprocedural management of the NOAC\u2019s"],"prefix":"10.1007","volume":"36","author":[{"given":"Gregory","family":"Connolly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex C.","family":"Spyropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,27]]},"reference":[{"issue":"Suppl 1","key":"911_CR1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2009.03389.x","volume":"7","author":"M Levi","year":"2009","unstructured":"Levi M (2009) Epidemiology and management of bleeding in patients using vitamin K antagonists. J Thromb Haemost 7(Suppl 1):103\u2013106","journal-title":"J Thromb Haemost"},{"issue":"2","key":"911_CR2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","volume":"36","author":"S Blech","year":"2008","unstructured":"Blech S et al (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36(2):386\u2013399","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"911_CR3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1160\/TH11-09-0656","volume":"107","author":"C Dansirikul","year":"2012","unstructured":"Dansirikul C et al (2012) A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. Thromb Haemost 107(4):775\u2013785","journal-title":"Thromb Haemost"},{"issue":"1 Suppl","key":"911_CR4","doi-asserted-by":"crossref","first-page":"119S","DOI":"10.1177\/0091270011415527","volume":"52","author":"S Hariharan","year":"2012","unstructured":"Hariharan S, Madabushi R (2012) Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 52(1 Suppl):119S\u2013125S","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"911_CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1185\/03007995.2011.654109","volume":"28","author":"A Clemens","year":"2012","unstructured":"Clemens A et al (2012) Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin 28(2):195\u2013201","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"911_CR6","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/dmd.108.025551","volume":"37","author":"D Lang","year":"2009","unstructured":"Lang D, Freudenberger C, Weinz C (2009) In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos 37(5):1046\u20131055","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"911_CR7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","volume":"70","author":"D Kubitza","year":"2010","unstructured":"Kubitza D et al (2010) Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 70(5):703\u2013712","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"911_CR8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883\u2013891","journal-title":"N Engl J Med"},{"issue":"19","key":"911_CR9","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","volume":"32","author":"KA Fox","year":"2011","unstructured":"Fox KA et al (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 32(19):2387\u20132394","journal-title":"Eur Heart J"},{"issue":"12","key":"911_CR10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139\u20131151","journal-title":"N Engl J Med"},{"issue":"9","key":"911_CR11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/00498250500250493","volume":"35","author":"C Weinz","year":"2005","unstructured":"Weinz C et al (2005) Pharmacokinetics of BAY 590-7939: an oral, direct factor Xa inhibitor: in rats and dogs. Xenobiotica 35(9):891\u2013910","journal-title":"Xenobiotica"},{"issue":"5","key":"911_CR12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.cct.2006.04.005","volume":"27","author":"PF Boudes","year":"2006","unstructured":"Boudes PF (2006) The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemp Clin Trials 27(5):432\u2013440","journal-title":"Contemp Clin Trials"},{"issue":"10","key":"911_CR13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.7326\/0003-4819-155-10-201111150-00003","volume":"155","author":"S Schulman","year":"2011","unstructured":"Schulman S et al (2011) Warfarin dose assessment every 4\u00a0weeks versus every 12\u00a0weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 155(10):653\u2013659 W201-3","journal-title":"Ann Intern Med"},{"issue":"9745","key":"911_CR14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L et al (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376(9745):975\u2013983","journal-title":"Lancet"},{"issue":"1","key":"911_CR15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366(1):9\u201319","journal-title":"N Engl J Med"},{"issue":"8","key":"911_CR16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365(8):699\u2013708","journal-title":"N Engl J Med"},{"issue":"9","key":"911_CR17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364(9):806\u2013817","journal-title":"N Engl J Med"},{"issue":"24","key":"911_CR18","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342\u20132352","journal-title":"N Engl J Med"},{"issue":"19","key":"911_CR19","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","volume":"363","author":"SJ Connolly","year":"2010","unstructured":"Connolly SJ et al (2010) Newly identified events in the RE-LY trial. N Engl J Med 363(19):1875\u20131876","journal-title":"N Engl J Med"},{"issue":"5","key":"911_CR20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","volume":"172","author":"K Uchino","year":"2012","unstructured":"Uchino K, Hernandez AV (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172(5):397\u2013402","journal-title":"Arch Intern Med"},{"issue":"1","key":"911_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","volume":"154","author":"JV Freeman","year":"2011","unstructured":"Freeman JV et al (2011) Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 154(1):1\u201311","journal-title":"Ann Intern Med"},{"issue":"4","key":"911_CR22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1160\/TH10-01-0071","volume":"104","author":"A Diamantopoulos","year":"2010","unstructured":"Diamantopoulos A et al (2010) Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost 104(4):760\u2013770","journal-title":"Thromb Haemost"},{"issue":"3","key":"911_CR23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11239-011-0561-1","volume":"31","author":"E Nutescu","year":"2011","unstructured":"Nutescu E, Chuatrisorn I, Hellenbart E (2011) Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 31(3):326\u2013343","journal-title":"J Thromb Thrombolysis"},{"issue":"13","key":"911_CR24","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2011-10-378950","volume":"119","author":"S Schulman","year":"2012","unstructured":"Schulman S, Crowther MA (2012) How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 119(13):3016\u20133023","journal-title":"Blood"},{"issue":"31","key":"911_CR25","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.2174\/138161210793563338","volume":"16","author":"JD Douketis","year":"2010","unstructured":"Douketis JD (2010) Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des 16(31):3436\u20133441","journal-title":"Curr Pharm Des"},{"issue":"6","key":"911_CR26","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","volume":"103","author":"J Ryn van","year":"2010","unstructured":"van Ryn J et al (2010) Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116\u20131127","journal-title":"Thromb Haemost"},{"issue":"1","key":"911_CR27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11239-009-0392-5","volume":"29","author":"MM Samama","year":"2010","unstructured":"Samama MM, Gerotziafas GT (2010) Newer anticoagulants in 2009. J Thromb Thrombolysis 29(1):92\u2013104","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"911_CR28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","volume":"49","author":"J Stangier","year":"2010","unstructured":"Stangier J et al (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49(4):259\u2013268","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"911_CR29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.111.090464","volume":"126","author":"JS Healey","year":"2012","unstructured":"Healey JS et al (2012) Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 126(3):343\u2013348","journal-title":"Circulation"},{"issue":"12","key":"911_CR30","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","volume":"48","author":"J Stangier","year":"2008","unstructured":"Stangier J et al (2008) Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 48(12):1411\u20131419","journal-title":"J Clin Pharmacol"},{"issue":"2 Suppl","key":"911_CR31","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","volume":"141","author":"JD Douketis","year":"2012","unstructured":"Douketis JD et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e326S\u2013e350S","journal-title":"Chest"},{"issue":"12","key":"911_CR32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/ajhp\/62.12.1247","volume":"62","author":"J Golembiewski","year":"2005","unstructured":"Golembiewski J, Chernin E, Chopra T (2005) Prevention and treatment of postoperative nausea and vomiting. Am J Health Syst Pharm 62(12):1247\u20131260 quiz 1261-2","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"911_CR33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1160\/TH08-10-0708","volume":"101","author":"JE Eikelboom","year":"2009","unstructured":"Eikelboom JE, Weitz JI (2009) Dabigatran etexilate for prevention of venous thromboembolism. Thromb Haemost 101(1):2\u20134","journal-title":"Thromb Haemost"},{"issue":"6","key":"911_CR34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/11587290-000000000-00000","volume":"34","author":"S Schulman","year":"2011","unstructured":"Schulman S, Majeed A (2011) A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. Drug Saf 34(6):449\u2013463","journal-title":"Drug Saf"},{"issue":"12","key":"911_CR35","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","volume":"61","author":"D Kubitza","year":"2005","unstructured":"Kubitza D et al (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939: an oral, direct Factor Xa inhibitor: after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61(12):873\u2013880","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"911_CR36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.fct.2009.09.036","volume":"48","author":"S Ananthi","year":"2010","unstructured":"Ananthi S et al (2010) In vitro antioxidant and in vivo anti-inflammatory potential of crude polysaccharide from Turbinaria ornata (Marine Brown Alga). Food Chem Toxicol 48(1):187\u2013192","journal-title":"Food Chem Toxicol"},{"issue":"7\u20138","key":"911_CR37","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1345\/aph.1Q105","volume":"45","author":"L Baruch","year":"2011","unstructured":"Baruch L, Sherman O (2011) Potential inaccuracy of point-of-care INR in dabigatran-treated patients. Ann Pharmacother 45(7\u20138):e40","journal-title":"Ann Pharmacother"},{"issue":"4","key":"911_CR38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1160\/TH10-10-0679","volume":"105","author":"BI Eriksson","year":"2011","unstructured":"Eriksson BI et al (2011) Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 105(4):721\u2013729","journal-title":"Thromb Haemost"},{"issue":"11","key":"911_CR39","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","volume":"5","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI et al (2007) Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5(11):2178\u20132185","journal-title":"J Thromb Haemost"},{"issue":"14","key":"911_CR40","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR Buller","year":"2012","unstructured":"Buller HR et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287\u20131297","journal-title":"N Engl J Med"},{"issue":"26","key":"911_CR41","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499\u20132510","journal-title":"N Engl J Med"},{"issue":"26","key":"911_CR42","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"BI Eriksson","year":"2008","unstructured":"Eriksson BI et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358(26):2765\u20132775","journal-title":"N Engl J Med"},{"issue":"9632","key":"911_CR43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","volume":"372","author":"AK Kakkar","year":"2008","unstructured":"Kakkar AK et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31\u201339","journal-title":"Lancet"},{"issue":"26","key":"911_CR44","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen MR et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358(26):2776\u20132786","journal-title":"N Engl J Med"},{"issue":"23","key":"911_CR45","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","volume":"365","author":"SZ Goldhaber","year":"2011","unstructured":"Goldhaber SZ et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365(23):2167\u20132177","journal-title":"N Engl J Med"},{"issue":"6","key":"911_CR46","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","volume":"361","author":"MR Lassen","year":"2009","unstructured":"Lassen MR et al (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361(6):594\u2013604","journal-title":"N Engl J Med"},{"issue":"26","key":"911_CR47","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","volume":"363","author":"MR Lassen","year":"2010","unstructured":"Lassen MR et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363(26):2487\u20132498","journal-title":"N Engl J Med"},{"issue":"15","key":"911_CR48","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood-2012-06-415943","volume":"120","author":"AC Spyropoulos","year":"2012","unstructured":"Spyropoulos AC, Douketis JD (2012) How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 120(15):2954\u20132962","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-013-0911-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-013-0911-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-013-0911-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T06:57:37Z","timestamp":1562828257000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-013-0911-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,27]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["911"],"URL":"https:\/\/doi.org\/10.1007\/s11239-013-0911-2","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,27]]}}}